Scientists Learn More about How Lung Cancer Becomes Resistant to Drugs
By switching from one cellular identity to another, lung cancer cells can evade targeted therapies. MSK scientists are trying to stop that from happening.
Molecular Atlas of Small Cell Lung Cancer Reveals Unusual Cell Type That Could Explain Why It’s So Aggressive
Stem-like cells that make up only a tiny fraction of the total cells in a lung tumor could be the key to stopping the disease’s deadly spread, say researchers at Memorial Sloan Kettering.
MSK Scientists Reveal Biology of Shape-Shifting Lung Cancer
Lung cancer has an uncanny ability to change its identity to resist drugs. Researchers are learning what drives these changes.
Memorial Sloan Kettering Announces New Initiative to Focus on Lung Cancer Research
MSK today announced a $20 million gift from the Ge Li & Ning Zhao Family Foundation to support lung cancer research and the development of new therapies to treat this disease.
In the Clinic
Unexpected Finding Reveals New Target for Aggressive Form of Lung Cancer
Researchers discover that a subset of lung adenocarcinomas are aggressive because of mutations that allow them to block ferroptosis, a type of cell death.
MSK Leaders Recognized in the 40 Under 40 in Cancer Class of 2020
Chief of the Melanoma Service Michael Postow, MD, Medical Oncologist Nitya Raj, MD, and Assistant Attending Triparna Sen, PhD were included on this year’s list.
ASCO 2020: Advances in the Treatment of Small-Cell Lung Cancer
During the upcoming ASCO Virtual Scientific Program, MSK Chief of Thoracic Oncology Service Charles M. Rudin, MD, PhD, will present a study that found pembrolizumab addition to first-line chemotherapy significantly improved progression-free survival for patients with small cell lung cancer (SCLC).
In the Lab
Scientists Home in on Treatment Advance for Chemotherapy-Resistant Small Cell Lung Cancer
An epigenetic mechanism may make small cell lung cancer vulnerable to a new kind of attack.